Clinical characteristics and outcomes of COVID-19 infection in Chinese patients with hematologic malignancies in the Omicron era
Hematology. 2023 Dec;28(1):2288477. doi: 10.1080/16078454.2023.2288477. Epub 2023 Dec 1.ABSTRACTPatients with hematologic malignancies are often immunodeficient and therefore have a higher risk of severe symptoms from coronavirus disease 2019 (COVID-19). We retrospectively examined a cohort of 289 patients from 16 hospitals in Zhejiang Province who had hematologic malignancies and COVID-19 during a period when the Omicron variant was predominant. Univariate analysis showed that some clinical characteristics, including elder age (P = 0.014), multiple comorbid conditions (P = 0.011), and receipt of active antineoplastic ther...
Source: Hematology - December 1, 2023 Category: Hematology Authors: Xian Li Aiqi Zhao Huifang Jiang Ying Lu Jing Le Yaping Xie Meiwei Hu Hui Zeng Jianzhi Zhao Mei Zhou Hui Zhou Lili Chen Weiguo Zhu Guifang Ouyang Huiqing Qiu Songfu Jiang Qunyi Guo Wenbin Qian Yun Liang Source Type: research
Diagnostic and prognostic value of ferroptosis-related genes in patients with Myelodysplastic neoplasms
This study delves into the emerging role of ferroptosis in Myelodysplastic Neoplasms (MDS) and aims to identify a prognostic ferroptosis-related gene signature for MDS. Utilizing RNA-seq data and clinical information from the Gene Expression Omnibus database, the researchers extracted ferroptosis-related genes from the FerrDb website and conducted differential expression analysis using the 'limma' package in R. Hub ferroptosis-related genes in MDS were screened using the "RandomForest" and "carat" R packages. Kaplan -Meier and Cox regression analyses were employed to assess the prognostic role of three identified hub genes...
Source: Hematology - December 1, 2023 Category: Hematology Authors: Xiaomei Chen Chao Li Yulian Wang Suxia Geng Maozhi Xiao Lingji Zeng Chengxin Deng Minming Li Xin Huang Jianyu Weng Xin Du Peilong Lai Source Type: research
Clinical characteristics and outcomes of COVID-19 infection in Chinese patients with hematologic malignancies in the Omicron era
Hematology. 2023 Dec;28(1):2288477. doi: 10.1080/16078454.2023.2288477. Epub 2023 Dec 1.ABSTRACTPatients with hematologic malignancies are often immunodeficient and therefore have a higher risk of severe symptoms from coronavirus disease 2019 (COVID-19). We retrospectively examined a cohort of 289 patients from 16 hospitals in Zhejiang Province who had hematologic malignancies and COVID-19 during a period when the Omicron variant was predominant. Univariate analysis showed that some clinical characteristics, including elder age (P = 0.014), multiple comorbid conditions (P = 0.011), and receipt of active antineoplastic ther...
Source: Hematology - December 1, 2023 Category: Hematology Authors: Xian Li Aiqi Zhao Huifang Jiang Ying Lu Jing Le Yaping Xie Meiwei Hu Hui Zeng Jianzhi Zhao Mei Zhou Hui Zhou Lili Chen Weiguo Zhu Guifang Ouyang Huiqing Qiu Songfu Jiang Qunyi Guo Wenbin Qian Yun Liang Source Type: research
Clinical profiles in multiple myeloma patients with extreme survivals: a study from a National Medical Center in China
CONCLUSIONS: The disparities in the survivals of MM patients indicated that some unexpected factors have influenced the outcomes in the real-world setting.PMID:38018564 | DOI:10.1080/16078454.2023.2277503 (Source: Hematology)
Source: Hematology - November 29, 2023 Category: Hematology Authors: Liang Ren Yuhong Ren Yang Yang Wenjing Wang Tianhong Xu Yawen Wang Jiadai Xu Aziguli Maihemaiti Tianwei Lan Panpan Li Chi Zhou Pu Wang Peng Liu Source Type: research
Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: a systematic literature review and meta-analysis
CONCLUSION: For NHL patients, there is no significant difference in the efficacy between subcutaneous rituximab and conventional therapy, while subcutaneous injection can shorten exposure time in the hospital and reduce the risk of infection.PMID:38010876 | DOI:10.1080/16078454.2023.2284047 (Source: Hematology)
Source: Hematology - November 27, 2023 Category: Hematology Authors: Tianyu Si Xiaolin Ma Wenwei Zhu Yongming Zhou Source Type: research
A review on characterization of BCR - ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes
Hematology. 2023 Dec;28(1):2284038. doi: 10.1080/16078454.2023.2284038. Epub 2023 Nov 20.ABSTRACTChronic myeloid leukemia (CML) is a clonal myeloproliferative growth of human pluripotent stem cells which is estimated to occur at a rate of 1/100000 populations every year worldwide. A characteristic feature of this disease is the presence of the Philadelphia chromosome genotype, which results from the reciprocal translocation between human chromosomes 9 and 22. Two types of major genotypes are involved, which consequently result in two major types of expressed fusion mRNA transcripts: b3a2 and b2a2, i.e. major breakpoint seg...
Source: Hematology - November 20, 2023 Category: Hematology Authors: Benyam Zenebe Helen Nigussie Gurja Belay Nigussie Seboka Source Type: research
Reaching the cyclosporine a level target slowly in four weeks correlates with better prognosis for Chinese patients after allogeneic haematopoietic cell transplantation
CONCLUSION: For Chinese patients, early introduction and reaching the target CsA concentration within four weeks after allo-HSCT have a positive effect on preventing GvHD, especially in the fourth week after HSCT. Compared to the Western population, the target CsA concentration is lower and the time required to reach the target (within 4 weeks) is longer in the Chinese population (274.75 ng/mL).PMID:37975575 | DOI:10.1080/16078454.2023.2275893 (Source: Hematology)
Source: Hematology - November 17, 2023 Category: Hematology Authors: Qingqing Fan Xiang Hui Xiang Li Qian Li Dihong Yang Yongqing Wang Source Type: research
